Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar Dose-Response in Japanese T2D
NCT00261417Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by AstraZeneca. Primary endpoint: Fasting Plasma Glucose. Started May 2004; status: terminated.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00261417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261417.